



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GENEGO IS AWARDED NIH GRANT FOR DISEASE NETWORK ALGORITHMS

St Joseph, Michigan, June 13th, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a Phase I SBIR grant from the National Institute of General Medical Science for development of methodologies intended for reconstruction of functional networks affected in common human diseases. In Phase I, GeneGo will generate and test novel algorithms enabling comparison of disease related OMICs datasets of different origin, based on networks topology and content.

“Analysis of human biological networks is an exciting new area of systems biology, and we are glad that our efforts are appreciated by the NIH”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “Common diseases have profound effects on both signaling and metabolic machinery, usually in more than one cell type. Because of this, the result detected by “genome scale” technologies such as microarray gene expression, proteomics and genotyping, is complex and multi-level. Each data type provides only one level of information, and total reconstruction of the “big picture” of molecular pathology is a major challenge. We will study conditional perturbations of the human interactome assembled from manually curated physical protein interactions and develop algorithms for assembly of complete functional networks, from membrane receptors to transcriptional factors and “core effector” metabolic pathways. We will test the approach on disease datasets in collaboration with the Van Andel Research Institute”.

"We are truly excited at this opportunity to collaborate with the GeneGo team. We believe that the integrated approach offered through GeneGo's advanced computational systems will be critical in deciphering the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine" said Dr. Craig Webb, a lab head at Van Andel and an advisor on the grant.

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company's original computational platform allows an integration and analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's first product, MetaCore™, assists scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. GeneGo's second product, MetaDrug™, is designed for medicinal chemists and enables prediction of metabolites and their likely toxicity in human..

For more information, please visit the company's Web site at www.genego.com .

MetaCore™, MetaDrug™ and MetaBase™ are trademarks of GeneGo, Inc.